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OBJECTIVES—To identify, map, clone, and functionally vali-
date a novel mouse model for impaired glucose tolerance and
insulin secretion.
RESEARCH DESIGN AND METHODS—Haploinsufﬁciency of
the insulin receptor and associated mild insulin resistance has
been used to sensitize an N-ethyl-N-nitrosourea (ENU) screen to
identify novel mutations resulting in impaired glucose tolerance
and diabetes. The new impaired glucose tolerance 4 (IGT4)
model was selected using an intraperitoneal glucose tolerance
test and inheritance of the phenotype conﬁrmed by generation of
backcross progeny. Segregation of the phenotype was correlated
with genotype information to map the location of the gene and
candidates sequenced for mutations. The function of the SRY-
related high mobility group (HMG)-box 4 (Sox4) gene in insulin
secretion was tested using another ENU allele and by small
interfering RNA silencing in insulinoma cells.
RESULTS—We describe two allelic autosomal dominant muta-
tions in the highly conserved HMG box of the transcription factor
Sox4. Previously associated with pancreas development, Sox4
mutations in the adult mouse result in an insulin secretory defect,
which exhibits impaired glucose tolerance in association with
insulin receptor
/–induced insulin resistance. Elimination of
the Sox4 transcript in INS1 and Min6 cells resulted in the
abolition of glucose-stimulated insulin release similar to that
observed for silencing of the key metabolic enzyme glucokinase.
Intracellular calcium measurements in treated cells indicate that
this defect lies downstream of the ATP-sensitive K
 channel
(KATP channel) and calcium inﬂux.
CONCLUSIONS—IGT4 represents a novel digenic model of
insulin resistance coupled with an insulin secretory defect. The
Sox4 gene has a role in insulin secretion in the adult -cell
downstream of the KATP channel. Diabetes 57:2234–2244,
2008
T
ype 2 diabetes is a heterogeneous metabolic
disorder characterized by hyperglycemia result-
ing from defects in insulin action and/or insulin
secretion with underlying genetic and environ-
mental causes. There has been some success in identifying
genetic factors underlying type 2 diabetes in some human
populations (for example, calpain 10, PPARG, KCNJ11,
TCF7L2, and ENPP1), and new whole-genome association
studies are identifying further new candidates; however,
many genes remain to be identiﬁed (1–8). One approach to
identifying new genes is to use the mouse as a model. For
example, using a combination of quantitative trait loci
mapping and mutagenesis techniques, we recently identi-
ﬁed a novel gene involved in insulin secretion (9–11).
Phenotype-driven N-ethyl-N-nitrosourea (ENU) mu-
tagenesis screens have proven to be a powerful and
efﬁcient tool for the identiﬁcation of novel models of
human disease (12,13). Mutations are introduced at a rate
of 1/1,000 (one functional mutation at any one locus in
1,000 mice), and each founder mutagenized mouse carries
30 such mutations (14–16). ENU is an alkylating agent
that preferentially induces A/T to T/A transversion muta-
tions at random across the genome; these point mutations
can create a variety of alleles, including hypomorphs,
hypermorphs, and loss or gain of function (17). Thus, ENU
could be used to introduce mutations into potentially any
gene in the genome that can be mutated to give rise to
diabetes or diabetes-related traits such as glucose intoler-
ance. As an example, new ENU-induced dominant muta-
tions in the key metabolic enzyme glucokinase (maturity
onset diabetes of the young 2 [MODY2]) have recently
been described (18,19) from large-scale dominant ENU
mutagenesis screens. Bru ¨ning et al. (20) showed that
double heterozygotes of null alleles of the insulin receptor
and insulin receptor substrate-1 led to the development of
overt diabetes in 40% of animals in contrast to single
heterozygotes. Diabetes development was dependent on
genetic background with C57BL/6J showing 85% transi-
tion to diabetes (21). We therefore decided to sensitize our
ENU mutagenesis screen by using mice heterozygous for
an insulin receptor knockout (22) maintained on a
C57BL/6J background, which exhibits mild insulin resis-
tance but not diabetes. Here, we describe two ENU-
induced mutations in the transcription factor Sox4 that
result in impaired glucose-stimulated insulin release lead-
ing to a mild impairment in glucose tolerance, and we also
show that one of these in combination with haploinsufﬁ-
ciency of the insulin receptor and associated insulin
resistance provide a novel digenic model that may have
relevance to the study of polygenic type 2 diabetes.
The SRY-related high mobility group (HMG)-box (SOX)
gene family is a group of important transcriptional regu-
lators of a number of developmental processes, including
the development of the endocrine pancreas (23). Mice
homozygous for a null mutation of Sox4 showed abnormal
pancreatic bud formation and endocrine cell differentia-
tion, and cultured pancreatic explants failed to form
normal islets. In wild-type animals, levels of Sox4 expres-
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2234 DIABETES, VOL. 57, AUGUST 2008sion peaked at embryonic day 13 and persisted at high
levels in adult islets. No role has yet been elucidated for
Sox4 in the adult pancreas.
RESEARCH DESIGN AND METHODS
Animal husbandry. Mice were kept in accordance with U.K. Home Ofﬁce
welfare guidelines and project license restrictions. Insulin receptor knockout
mice (22) were obtained from The Jackson Laboratories (Bar Harbor, ME) and
maintained as heterozygotes on a C57BL/6J background. MUD91 mice (a line
carrying an ENU-induced Sox4 allele from a developmental abnormality
screen) maintained on a mixed genetic background have been previously
reported (24).
ENU mutagenesis. Male mice heterozygous for the insulin receptor knock-
out mutation were treated with 2  100 mg/kg doses of ENU at 7-day intervals
(12). Lines were maintained by back-crossing to C3H/HeH mice.
Genotyping. Genomic DNA was extracted from mouse tail tissue using a
DNeasy tissue kit (Qiagen, West Sussex, U.K.) according to the manufacturer’s
instructions. A genome scan was performed with a panel of 140 microsatellite
markers spanning the mouse genome. Insulin receptor knockout mice were
genotyped using a generic neo PCR (The Jackson Laboratories). Genotypes
for both Sox4 alleles were conﬁrmed by sequencing, and gene fragments were
ampliﬁed using the following primers listed in a 5-3 orientation and se-
quenced: Y123C, GCAAGATCATGGAGCAGTC (SOX4F2) and GAGAACGAT-
GCAGCCG (SOX4Rbio); and S70P, GAGCACTTCAGCGGTGA (SOX4F1) and
GGAGATCTCGGCCGTTGT (SOX4R1).
Micro–magnetic resonance imaging. Embryos were dissected at 14.5 days
post coitum (dpc) into 37°C Hanks solution plus 5.0 mmol/l EDTA and allowed
to exsanguinate. Embryos were then ﬁxed in 4% paraformaldehyde in PBS
plus 2 mmol/l dimeglumine gadopentetate (Gd-DPTA; Magnevist) for several
days at 4°C. Before magnetic resonance imaging (MRI), the ﬁxed embryos
were embedded in 1% agarose in water with 2 mmol/l Gd-DPTA in 13-mm
(high-resolution single-embryo imaging) glass tubes. MRI was performed at an
experimental resolution of 9.7  9.7  12.7 m/voxel. MRI images were
archived as TIFF ﬁles on DVD and analyzed using AMIRA 4.1 software.
Intraperitoneal glucose tolerance tests. Mice were tested using the
EMPReSS simpliﬁed intraperitoneal glucose tolerance test (IPGTT) (http://
empress.har.mrc.ac.uk). Brieﬂy, mice were fasted overnight, and a fasted
blood sample was taken before intraperitoneal administration of a 2 g/kg
glucose load. Subsequent blood samples were taken over time (60 and 120 min
for glucose measurements or 10, 20, and 30 min for insulin measurements).
Plasma glucose was measured using an Analox Glucose Analyser GM9.
Plasma insulin was measured using a Mercodia Ultra-Sensitive Mouse
ELISA kit (Mercodia, Uppsala, Sweden) according to the manufacturer’s
instructions.
INS1 and Min6 cell culture. INS-1 cells (starting passage 30) were main-
tained in RPMI 1640 containing 5.5 mmol/l glucose (Gibco, Paisley, U.K.) and
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 g/ml streptomycin. Cells were incubated in humidiﬁed 5%
CO2, 95% air at 37°C.
MIN6 cells (starting passage 30) were maintained in Dulbecco’s modiﬁed
Eagle’s medium containing 25 mmol/l glucose and supplemented with 15%
heat-inactivated FBS in humidiﬁed 5% CO2, 95% air at 37°C.
Islet isolation. Mice were killed by cervical dislocation, the pancreases were
removed, and islets were isolated by liberase digestion and handpicking (25).
Cells were maintained in this medium at 37°C in a humidiﬁed atmosphere at
5% CO2 in air and used 1–2 days after the isolation.
Small interfering RNA. Synthetic small interfering RNAs (siRNAs) were
designed by Ambion and synthesized by both Ambion and Eurogentec. A total
of four siRNAs were used: nonsense, glucokinase (Gck), and two Sox4
siRNAs. Each siRNA had a Cy3 tag on the 5 end of the sense strand to enable
visualization of transfected cells. siRNA duplexes (500 nmol/l) were trans-
fected into INS1 and MIN6 cells using Lipofectamine 2000 (Invitrogen, Paisley,
U.K.) at 100 mol/l. Cells were cultured in RPMI 1640 (FBS free) for a further
24 h before experiment. siRNA sequences used listed in a 5 to 3 orientation
as follows: Sox4(1), GGACAGCGACAAGAUUCCGtt (forward) and CGGAA
UCUUGUCGCUGUCCtt (reverse); Sox4(2), GGAGAGGAGAGAGGGAAAAtt
(forward) and UUUUCCCUCUCUCCUCUCCtg (reverse); Gck, ACGU
AGGUGGGCAACAUCUtt (forward) and AGAUGUUGCCCACCUACGUtt
(reverse); and Nonsense, GGUCUAGUCUUCGGUCUUGtt (forward) and
CAAGACCGAAGACUAGACCtt (reverse).
Fura-2 calcium imaging. INS1 cells were cultured on 35-mm Fluorodishes
(World Precision Instruments) and incubated with 3 mol/l Fura-2-AM (Mo-
lecular Probes) for 40 min at 37°C. They were imaged at room temperature
(20–24°C) using an IonOptix ﬂuorescence system (IonOptix, Boston, MA),
with 340- and 380-nm dual excitation. The 510-nm emission ratio was collected
at 1 Hz. Background subtraction was performed by measuring ﬂuorescence
from a cell-free region in the ﬁeld of view. Cells were perfused continuously
with extracellular solution containing 137 mmol/l NaCl, 5.6 mmol/l KCl, 2.6
mmol/l CaCl2, 1.2 mmol/l MgCl2, and 10 mmol/l HEPES (pH 7.4 with NaOH)
plus glucose or tolbutamide as indicated. Only data from cells that responded
to 200 mol/l tolbutamide were analyzed.
Insulin secretion. INS1 or Min6 cells (1  10
5) were re-plated, transfected
with various siRNAs, and cultured for 24 h (as above) before being used in
secretion assays. Islets were isolated from wild-type and mutant mice and
cultured overnight (as described above) before insulin secretion was as-
sessed. Insulin secretion per group of ﬁve islets was measured during 1-h
static incubations in Krebs-Ringer buffer (118.5 mmol/l NaCl, 2.54 mmol/l
CaCl2, 1.19 mmol/l KH2PO4, 4.74 mmol/l KCl, 25 mmol/l NaHCO3, 1.19 mmol/l
MgSO4, and 10 mmol/l HEPES, pH 7.4) containing 0, 2, or 20 mmol/l glucose
or 0.2 mmol/l tolbutamide in the presence of 2 mmol/l glucose. Each glucose
concentration was replicated three times per individual. Samples of the
supernatant were assayed for insulin. To determine total insulin content,
insulin was extracted using 95:5 ethanol:acetic acid. Insulin was measured
using an Ultra-Sensitive Mouse Insulin ELISA kit (Mecodia).
Quantitative RT-PCR. Total RNA from isolated islets and siRNA-transfected
INS1 and MIN6 cells was extracted using a RNeasy mini-kit (Qiagen). cDNA
generated by Superscript II enzyme (Invitrogen) was analyzed by quantitative
RT-PCR using the TaqMan system based on real-time detection of accumu-
lated ﬂuorescence (ABI Prism 7700; Perkin-Elmer). Gene expression was
normalized relative to the expression of glyceraldehyde-3-phosphate dehydro-
genase (Gapdh). Inventoried Taqman Probes with FAM tags were purchased
from Applied Biosystems.
Samples were tested in triplicate, and results are expressed relative to
Gapdh. The Student’s t test was used to measure the signiﬁcance between
wild-type and Sox4 heterozygous islet cDNA (three biological replicates for
each group) when ampliﬁed for Camk2b, Cdc42, Glut2, Glut4, Gpx-1, Ins1,
Ins2, Kir6.2, NeuroD1, Nkx6.1, Pax6, PDX1, Prkci, Rab27, Sox4, Sur1, and
Syt9 gene expression. Islet cDNA ampliﬁed for Glut4, Rab27, and Syt9 was
ﬁrst preampliﬁed using a Taqman PreAmp Master Mix (Applied Biosystems).
The Student’s t test was also used to measure the signiﬁcance between
nonsense siRNA-transfected INS1 cells, Gck siRNA-transfected INS1 cells, and
Sox4 siRNA-transfected INS1 cells when amplifying for either Gck or Sox4
gene expression.
Complementation test and embryonic phenotype analysis. Males het-
erozygous for the Y123C Sox4 mutation were crossed to females heterozygous
for the same mutation, the S70P mutation, and the Del(13)Svea36H deletion.
Embryo dissections were carried out at 9.5, 13.5, and 14.5 dpc, and the
embryonic phenotype was visually analyzed. Tissue was collected from
individual embryos and the samples genotyped by sequencing as described
above.
Electron microscopy. After preparation (see above), isolated islets (30–40
per animal) were left to recover in pancreatic islet medium (hCell Technol-
ogy) for1ha t37°C. Islets were then washed in PBS and ﬁxed in cold 2.5%
glutaraldehyde in PBS for1ha t4°C, after which they were washed twice in
PBS. Osmium tetroxide at 1% in PBS was then added to the islets for1ha t
4°C, followed by washing twice with PBS. The islets were then left in PBS at
4°C overnight. Finally, islets were dehydrated in increasing concentrations of
ethanol (50, 70, 90, and 100%) for 5–10 min each and then embedded in
increasing concentrations of resin (50% ethanol/50% Agar 100 resin mix [48%
Agar 100 resin, 26% dodecenyl succinic anhydride, 26% methyl nadic anhy-
dride; Agar Scientiﬁc], 25% ethanol/75% resin, and 100% resin) for 5–10 min
each. Islets were left in 100% resin (resin plus 2% benzyl dimethylamine) at
least overnight at room temperature before ultra-thin sections were cut for
electron microscopy.
Islet immunohistochemistry. Immunohistochemistry was carried out on
parafﬁn sections of 17-week-old pancreas. A rabbit or goat (depending on
primary antibody) ABC staining system (Santa Cruz Biotechnology) was used
according to manufacturer’s instructions. The following primary antibodies
were used: rabbit anti-insulin (1:50; Santa Cruz Biotechnology), rabbit anti-
human glucagon (1:40; AbD Serotec), rabbit anti-somatostatin (2 g/ml;
Chemicon International), rabbit anti-PDX1 (1:500; Abcam), goat anti–Nkx-6.1
(1:50; Santa Cruz Biotechnology), goat anti-NeuroD (1:50; Santa Cruz Biotech-
nology), rabbit anti-MafA (1:500; Bethyl Laboratory), and rabbit anti-Glut2
(1:2,000; Chemicon International). Sections were counterstained with Gill’s
formulation no. 2 hematoxylin.
Islet area analysis. The pancreas from each mouse was ﬁxed in neutral
buffered formaldehyde (Surgipath Europe) and mounted in wax longitudinally
using the spleen for orientation. Serial sections were cut from each pancreas,
and every 20th section was stained with hematoxylin-eosin (H-E) (mounting,
cutting, and staining was carried out by Medical Solutions, Nottingham, U.K.).
Ten H-E–stained sections from each mouse were photographed completely,
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RESULTS
Sensitized ENU mutagenesis screen. Haploinsufﬁ-
ciency of the insulin receptor leading to insulin resistance
but not diabetes was used for a sensitized ENU phenotype-
driven screen. Male INSR
/ mice heterozygous for the
insulin receptor knockout (insulin receptor
/)o na
C57BL/6J genetic background were treated with two doses
of 100 mg/kg ENU separated by 7 days. Upon regaining
fertility, they were mated with C3H/HeH females, and up
to 50 F1 offspring per male were generated. A total of 789
male F1 offspring heterozygous for the insulin receptor
knockout mutation were assayed for glucose tolerance at
12 and 24 weeks of age by IPGTT. Fourteen male mice
were identiﬁed with impaired glucose tolerance and were
tested for inheritance of the phenotype by backcrossing to
C3H/HeH females (impaired glucose tolerance [IGT] lines
1–14). Five phenotypes were conﬁrmed as inherited in the
ﬁrst backcross generation (data not shown).
Mapping line IGT4 and identiﬁcation of a mutation.
One of the lines clearly associated with an impaired
glucose tolerance phenotype was IGT4. The causative
mutation was initially mapped to chromosome 13 using 16
backcross animals and a panel of 140 microsatellite mark-
ers. An additional 67 second-backcross animals reﬁned the
candidate region to 5.4 Mb (25.9–31.3 Mbp). Analysis of
the candidate region using the Ensembl database (http://
www.ensembl.org/Mus_musculus/index.html Build 27)
identiﬁed 39 genes, including a large cluster of prolactin-
like genes that were excluded from analysis because they
are unlikely candidates for a glucose tolerance phenotype.
The remaining eight genes were sequenced in the F1
founder mouse to identify the ENU-induced causative
mutation. A single A to G mutation was found at nucleo-
tide position 1,025 (A1025G), resulting in a tyrosine to
cysteine substitution at amino acid 123 (Y123C), which lies
in the highly conserved HMG-binding domain of the tran-
scription factor Sox4 (Fig. 1).
Sox4 homozygous mutant mice have an embryonic-
lethal phenotype. Embryos homozygous for the IGT4
Sox4 Y123C mutation die in utero at 14.5 dpc. An addi-
tional mutant allele of Sox4 (MUD91) carryingaTt oC
transition at nucleotide 869 (T869C), resulting in a serine
to proline substitution at amino acid 70 (S70P), was
available from a developmental phenotype screen at Har-
well (24). Both mutations alter highly conserved amino
acids within the HMG binding domain of Sox4 and are
predicted to abolish the DNA binding ability of the mutant
proteins (Fig. 1). Embryos homozygous for Mud91 Sox4
S70P die in utero at 14.5 dpc because of circulatory failure
(24).
Analysis of the embryonic phenotype shows no differ-
ence between embryos homozygous for either of the two
alleles. We therefore decided to test whether the two
mutations complement each other by breeding compound
heterozygotes. We found that Y123C/S70P mice exhibit the
same embryonic phenotype as the homozygotes for either
mutation (Table 1). We also tested the IGT4 Sox4 Y123C
mutation by breeding it in trans with a deletion that spans
the Sox4 gene (Del(13)Svea36H) and again observed
embryonic lethality indistinguishable from that of the two
homozygous Sox4 mutants. The Mud91 Sox4 S70P allele
in trans with a deletion that spans the Sox4 gene
(Del(13)Svea36H) was previously shown to be embryonic
lethal (26).
To further ascertain the nature of the IGT4 cardiac
phenotype, we analyzed IGT4 Sox4 Y123C/Del(13)Svea36H
embryos at 14.5 dpc by micro-MRI (MRI). IGT4 Sox4
Y123C/Del(13)Svea36H embryos showed external edema
(Fig. 2). Cardiac defects observed by MRI included an
outlet ventricular septal defect, dysplastic atrioventricular
valves, a double-outlet right ventricle, and a hypoplastic or
interrupted aortic arch (Fig. 2). Of the IGT4 Sox4 Y123C/
Del(13)Svea36H embryos, 60% also showed a cleft palate,
1               57                    135  152                     227                                      333             397  474
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FIG. 1. Schematic of Sox4 gene structure and position of Sox4 mutations within the highly conserved HMG DNA binding domain.
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bilateral hypoplasia of the thymus. Apart from a primum
atrial septal defect, only found in the Mud91 Sox4 S70P, these
MRI results are consistent with the ﬁndings in embryos
homozygous for Mud91 Sox4 S70P (24). The results are a
phenocopy of the range of cardiac defects previously de-
tected in the targeted allele of Sox4, but additionally we
detected dysplastic atrioventricular valves that have not been
described in the Sox4 knockout embryos (27,28).
The failure of these mutations to complement either
each other or a deletion of the Sox4 gene demonstrates
that IGT4 Sox4 Y123C mutation affects gene function.
Moreover, the fact that the mutation gives the same
embryonic phenotype when in trans with a deletion
suggests that IGT4 Sox4 Y123C mutation is a null.
Sox4 heterozygous mutant mice show impaired glu-
cose tolerance and reduced insulin secretion. Glucose
tolerance was assayed using an IPGTT with glucose mea-
sured at 0 min (T0), 60 min (T60), and 120 min (T120).
Male mice heterozygous for both the insulin receptor
knockout (insulin receptor
/) and the IGT4 Sox4 Y123C
mutant allele exhibited impaired glucose tolerance in an
IPGTT test at 12 weeks of age (Fig. 3A). Glucose levels
were signiﬁcantly different from wild-type or insulin recep-
tor
/ littermates at all three time points examined (T0,
P  0.05; T60, 0.001; and T120, 0.001). The existence of
the Mud91 Sox4 S70P allele allowed us to test whether a
different Sox4 mutation also affected glucose tolerance
(Fig. 3B). Inheritance of either of the Sox4 mutant alleles
(Y123C or S70P) alone and in the absence of the insulin
receptor mutation increased glucose levels signiﬁcantly
compared with wild-type or insulin receptor
/ littermates
60 min after glucose administration (P  0.05), with levels
failing to return to normal levels in Y123C mice after 120
min (Fig. 3A and B). Glucose intolerance observed in two
independently derived alleles of Sox4 conﬁrms that the
phenotype is caused by the identiﬁed mutations. In the
case of the IGT4 Sox4 Y123C mutation, the presence of the
insulin receptor
/ signiﬁcantly increased blood glucose
concentrations in an IPGTT, demonstrating a sensitizing
effect of the insulin receptor
/ knockout (Fig. 3A). To
investigate whether there was a defect in insulin secretion
that might account for the glucose intolerance, we mea-
sured insulin secretion for both Sox4 alleles (Y123C or
S70P). This was carried out in the absence of the insulin
receptor
/ mutation using a 30-min glucose tolerance test
with blood samples taken and glucose and insulin levels
measured at T0, T10, T20, and T30 (Fig. 3C and D). Both
lines showed signiﬁcantly elevated glucose levels (Fig. 3C)
at T20 and T30 (P  0.001) and secreted signiﬁcantly lower
levels of insulin (Fig. 3D) in response to a glucose chal-
lenge compared with wild type at T10, T20, and T30 (P 
0.01).
To further conﬁrm a defect in insulin secretion, we
measured glucose-stimulated insulin secretion in isolated
islets from mice carrying the IGT4 Sox4 Y123C mutation
(Fig. 4). Basal insulin secretion was the same as wild-type
littermate control islets. However, incubation in 20 mmol/l
glucose stimulated signiﬁcantly less insulin secretion from
mutant compared with wild-type littermate islets (P 
0.05). Furthermore, the response to the sulfonylurea tol-
butamide was also signiﬁcantly impaired, but not to the
same extent as observed in 20 mmol/l glucose (Fig. 4).
There was no signiﬁcant difference in total insulin content
between mutant and wild-type islets (Supplemental Fig. 1,
available in the online appendix at http://dx.doi.org/
10.2337/db07-0337). Because tolbutamide closes ATP-
sensitive K
 channels (KATP channels) directly, this result
suggests that the insulin secretory defect observed in Sox4
heterozygous mutant mice lies downstream of KATP chan-
nel closure. Insulin secretion in insulin receptor heterozy-
gous controls was signiﬁcantly higher at all points,
consistent with increased in vivo insulin secretion (Fig.
3D). Additionally, insulin receptor islets showed reduced
total insulin content (P  0.001; Supplemental Fig. 1).
Sox4 heterozygous animals form normal islets. Pan-
creatic sections from Sox4-heterozygous animals and wild-
type littermates were examined for differences in both
islet mass and architecture. There was no signiﬁcant
difference between wild-type and heterozygous IGT4 Sox4
Y123C mice in their percentage of islet areas (the percent-
age of a histological section identiﬁed as islet; Table 2).
Histological staining showed no qualitative difference in
islet architecture in terms of arrangement or relative
numbers of 	-, -, or 
-cells (Fig. 5). Transmission electron
microscopy of islets from Sox4-heterozygous animals and
wild-type littermates at 12 weeks of age showed no
obvious differences (Supplemental Fig. 2). Quantitative
RT-PCR analysis of islet RNA showed an increase in Sox4
expression that just reaches signiﬁcance (P  0.045) and
no difference in expression levels of a number of key -cell
target genes, including insulin (Supplemental Fig. 3).
siRNA knockdown of Sox4 in INS1 cells. To further
validate the in vivo and isolated islet data, we investigated
the effect of loss of Sox4 gene expression in a rat insulin-
secreting cell line INS1 using RNA interference (siRNA) to
knock down the expression of the endogenous Sox4 gene.
INS1 cells were transfected with one of four siRNA
duplexes: nonsense (negative control), Gck (positive con-
trol), or two different Sox4-speciﬁc siRNAs [Sox4(1) and
Sox4(2)]). All siRNAs were tagged with Cy3 ﬂuorescent
dye to enable transfected cells to be easily detected.
TABLE 1
Result of embryonic phenotype analysis and complementation tests
Heterozygous
cross
Stage
(dpc)
Affected
embryos (two
mutant alleles)
Unaffected
embryos (two
mutant alleles)
Unaffected embryos
(wild-type alleles)
S70P X Y123C 9.5 1 1 9
S70P X Y123C 13.5 5 1 18
Y123C X Y123C 9.5 2 2 16
Y123C X Y123C 14.5 2 0 3
Del X Y123C 13.5 2 1 5
Data are n. Males heterozygous for the Y123C Sox4 mutation were crossed to females heterozygous for the same mutation, the S70P mutation,
and the Del(13)Svea36H deletion. Embryo dissections were carried out at 9.5, 13.5, and 14.5 dpc, and the embryonic phenotype was visually
analyzed.
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DIABETES, VOL. 57, AUGUST 2008 2237FIG. 2. IGT4 embryos at 14.5 dpc. A: Wild-type embryo. B: Mutant IGT4 Sox4 Y123C/Del(13)Svea36H embryo showing severe edema. C and D:
Transverse MRI sections through a Sox4 wild-type (C) and mutant (D) embryo at the level of the AV valves at 14.5 dpc. C: In the wild-type
embryo, the left (LV) and right (RV) ventricle are separated by the interventricular septum (IVS), and the left (LA) and right (RA) atrium are
separated by the primary atrial septum (PAS). D: In a corresponding section of a mutant embryo, a ventricular septal defect (VSD) can be seen.
The mitral valve (MV) and the tricuspidal valve (TV) are dysplastic. E and F: Three-dimensional reconstructions of a wild-type (E) and a mutant
(F) heart at 14.5 dpc. In the wild-type heart (E), the aorta (Ao) originates from the left ventricle (LV), and the pulmonary artery (PA) originates
from the right ventricle (RV). The left (LVOT) and right ventricular outﬂow tract (RVOT) are indicated. The PA connects to the descending aorta
(dAo) via the ductus arteriosus. In the mutant (F), a ventricular septal defect (VSD) connects the LV and RV. The Ao and PA both originate from
the RV (double-outlet right ventricle). The aortic arch (AoA) does not connect to the descending aorta (dAo), showing an interrupted aortic arch
(IAoA). Note also the dilated PA. Axes: D, dorsal; V, ventral; A, anterior; P, posterior; L, left; R, right. (Please see http://dx.doi.org/10.2337/
db07-0337 for a high-quality digital representation of this ﬁgure.)
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conﬁrmed by quantitative real-time PCR. Expression of
Gck and Sox4 mRNAs was abolished by siRNAs targeted
against these genes, but neither was affected in INS1 cells
transfected with nonsense siRNA (Fig. 6A and B). Basal
insulin secretion was the same for all transfected cells
(Fig. 6C), and siRNA knockdown had no effect on total
insulin content compared with nonsense transfected cells
(Supplemental Fig. 4). Nonsense siRNA-transfected INS1
cells responded to incubation in both 2 and 20 mmol/l
glucose by secreting increasing amounts of insulin. In
comparison, glucose-stimulated insulin secretion at 2 and
20 mmol/l glucose was signiﬁcantly reduced for both
nonoverlapping Sox4 siRNA duplexes and for the Gck-
positive control compared with wild type (Fig. 6C). There
was a signiﬁcant reduction in insulin secretion from Sox4
siRNA-transfected INS1 cells in response to tolbutamide
compared with nonsense siRNA-transfected cells. This
was not observed with Gck-transfected cells (Fig. 6C).
These results resemble those found for isolated Sox4
mutant islets (Fig. 4). These experiments have been re-
peated in the mouse insulinoma cell line Min6 with the
same results (Supplemental Figs. 4–6).
Intracellular calcium measurements. To further char-
acterize the glucose-stimulated insulin secretory defect in
Sox4 siRNA-transfected INS1 cells, we measured changes
in intracellular calcium concentration [Ca
2]i in response
to incubation in increasing glucose concentrations. In
Sox4 (duplexes 1 and 2), nonsense, and mock-transfected
cells, glucose concentrations 2 mmol/l elicited a rise in
[Ca
2]i, and this was abolished, as expected, in cells
transfected with Gck siRNA (Fig. 7). These data suggest
that the secretory defect lies downstream of the KATP
channels, calcium inﬂux that follows channel closure, and
membrane depolarization.
DISCUSSION
Sox4 is a transcription factor that is expressed in the
pancreas (29,23). Embryos null for Sox4 show normal
pancreatic bud formation and endocrine cell differentia-
tion up to 12.5 dpc (23). However, after this stage, they
failed to form normal islets, and there was a lack of proper
expansion of the endocrine cell population and particu-
larly of -cells (23). Breeding of compound heterozygotes
(IGT4 Sox4 Y123C and Mud91 Sox4 S70P) and crossing
both alleles with the chromosome deletion del36H con-
ﬁrms that both Sox4 mutations, as predicted, affect the
function of the protein. The observation of glucose intol-
erance in the two independent heterozygous ENU alleles
also conﬁrms that the ENU mutation accounts for the
phenotype, and the likelihood of other ENU mutations
being present within the mapped region is very low (16).
The role of Sox4 in the adult islet is unknown.
Random ENU mutagenesis has proven to be an effective
tool in the identiﬁcation of novel mouse models of human
disease (12,13). In our sensitized approach, which used a
mouse knockout exhibiting insulin resistance but not
diabetes and a sensitive phenotypic assay (IPGTT), we
have successfully identiﬁed a novel mouse model for
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FIG. 3. Plasma glucose measured in IPGTT in male mice at 12 weeks of age. A: Animals heterozygous for the Sox4Y123C mutation show impaired
glucose tolerance (#P < 0.05) compared with wild-type littermates. The phenotype is exacerbated in mice also carrying a heterozygous insulin
receptor (IR) knockout. Insulin receptor and Sox4 Y123C, purple squares, n  20; IR
/ only, blue stars, n  21; Sox4 Y123C, red circles, n  15;
wild-type littermates, black triangles, n  15. B: Animals heterozygous for the Sox4S70P mutation show impaired glucose tolerance compared
with wild-type littermates. Sox4S70P, green diamonds, n  15; compared with wild-type littermate, black triangles, n  23. C: Both lines exhibit
signiﬁcantly higher plasma glucose concentrations measured at 20 and 30 min of an IPGTT. Sox4 Y123C, red circles, n  12; Sox4S70P, green
diamonds, n  9; IR only, blue stars, n  9; wild-type littermate, black triangle, n  24. D: Insulin secretion measured during a 30-min IPGTT. Both
lines show impaired glucose stimulated insulin release. Statistical signiﬁcance of Sox4 Y123C mice versus wild-type littermates and Sox4S70P
mice versus wild-type littermates is indicated by *P < 0.05, **P < 0.01, and ***P < 0.001 (Student’s t test). Insulin secretion from IR
/ mice was
signiﬁcantly different at all time points (##P < 0.01). Wild-type littermates from S70P and Y123P lines were not statistically signiﬁcantly
different from each other and were pooled in C and D. All data are expressed as means  SE.
M. GOLDSWORTHY AND ASSOCIATES
DIABETES, VOL. 57, AUGUST 2008 2239impaired glucose tolerance and cloned the underlying
gene. Mice heterozygous for either ENU mutated allele of
Sox4 (Y123C or S70P) exhibited a statistically signiﬁcant
impairment in glucose tolerance at 12 weeks of age.
IPGTT testing of mice heterozygous for a null mutation
of Sox4 has been reported to have nonsigniﬁcant differ-
ences in glucose tolerance at the 30-min time point of the
test; however, there was a clear trend of increased blood
glucose concentrations in heterozygotes at all of the
IPGTT time points after fasting shown (23). It should be
noted that the genetic background of these mice is differ-
ent. Furthermore, Wilson et al. (23) carried out IPGTT
tests using a 1 g/kg glucose challenge, lower than the 2
g/kg that we used, and this may have also contributed to
the differences we observed.
Both ENU-induced mutations in Sox4 (S70P and Y123C)
were signiﬁcantly glucose intolerant because of impaired
glucose-stimulated insulin secretion. This reduction in
glucose-stimulated insulin release was also observed in
isolated islets from IGT4 Sox4 Y123C mutant mice when
compared with wild-type littermates. Knockdown of Sox4
in insulinoma cells with two different siRNAs targeted to
separate regions of the gene abolished glucose-stimulated
insulin release, as did siRNA knockdown of the key
metabolic enzyme Gck. Changes in [Ca
2]i evoked by
glucose, however, were normal in Sox4 mutant cells,
indicating that KATP channels close normally. This sug-
gests the insulin secretory defect lies downstream of
calcium signal and may represent, for example, a defect in
triggering exocytosis. Electron microscopy analysis, how-
ever, did not reveal any gross abnormalities in vesicles or
their distribution.
Tolbutamide stimulates insulin secretion in pancreatic
-cells by closing KATP channels in the plasma membrane
directly, leading to membrane depolarization and activa-
tion of voltage-gated calcium channels. This results in
calcium inﬂux and a rise in intracellular calcium ([Ca
2]i)
that triggers insulin release. We observed a signiﬁcant
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FIG. 4. Insulin secretion from islets isolated from Sox4 Y123C mutant (black diagonal stripe bars), insulin receptor heterozygotes (black bars),
and wild-type littermates (white bars) in response to glucose (0, 2, or 20 mmol/l) or 200 mol/l tolbutamide (tol) normalized to total insulin
content. Islets were isolated from ﬁve mice of each genotype. The data represent the mean of ﬁve animals (with three technical replicates per
animal and each replicate comprising ﬁve islets  SE). Statistical analysis by Student’s t test, where *P < 0.05 and **P < 0.01.
TABLE 2
Pancreatic islet area in 17-week-old male mice
Genotype Total sectional area* Total islet area* Islets (n) Islet area (%)
Sox4 Y123C 6,707,744 76,493 173 1.14
Sox4 Y123C 4,582,464 56,548 124 1.23
Sox4 Y123C 7,077,281 141,769 199 2.00
Total 18,367,489 274,810 496 1.50
Wild-type littermate 6,960,257 138,588 245 1.99
Wild-type littermate 6,163,259 58,314 170 0.95
Wild-type littermate 5,752,898 97,481 151 1.69
Total 18,876,414 294,383 566 1.56
Data are n and percent. The pancreas was mounted longitudinally and serially sectioned with every 20th section stained with H-E, resulting
in 10 sections from each of 3 mutant mice (Sox4Y123C) and 3 wild-type mice (60 whole sections). *Arbitrary units based on pixel values.
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2240 DIABETES, VOL. 57, AUGUST 2008reduction in tolbutamide-stimulated insulin secretion both
in isolated mutant islets and in Sox4 siRNA–treated INS1
or Min6 cells compared with wild-type cells, consistent
with a defect downstream of the KATP channel. However,
insulin secretion by mutant islets or siRNA-treated insuli-
noma cells was signiﬁcantly more stimulated by tolbut-
amide than by 20 mmol/l glucose treatment (Figs. 4 and 6;
Supplemental Fig. 5). It is known that at higher tolbut-
amide concentrations, there is stimulation of insulin exo-
cytosis by direct interaction with the secretory machinery
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FIG. 5. Immunohistochemistry on parafﬁn sections of 17-week-old pancreas. Images show wild-type and Sox4 heterozygous animals stained with
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Gill’s formulation no. 2 hematoxylin. (Please see http://dx.doi.org/10.2337/db07-0337 for a high-quality digital representation of this ﬁgure.)
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channel. This mechanism may explain why the inhibition
of tolbutamide-stimulated insulin secretion by the Sox4
mutation is not as strong as that observed for glucose
alone (30).
The glucose intolerance caused by the IGT4 Sox4 Y123C
mutation is made worse by the presence of the heterozy-
gous insulin receptor null mutation. This may in part be a
contribution of insulin receptor haploinsufﬁciency to insu-
lin resistance in key tissues, such as liver, adipose tissue,
and muscle, that reduces glucose tolerance, further com-
pounding lower glucose-stimulated insulin secretion.
However, the insulin receptor is important in -cell func-
tion, as shown by tissue-speciﬁc knockout of this gene that
results in decreased acute insulin secretion and in impair-
ment of glucose tolerance (31). Martinez et al. (32) have
shown that the transcription factor Foxo1 is regulated in
the -cell by glucose but that this requires the insulin
receptor. The Sox4 mutations outlined in this work have
an effect on glucose-stimulated insulin secretion in the
absence of the insulin receptor heterozygous null muta-
tion, so although we cannot rule out a sensitizing effect in
the -cell when the insulin receptor
/ mutation is
present, it is not a requirement for impairment. The IGT4
model in combination with insulin receptor
/ shows the
effect of multiple mutations on glucose intolerance. This is
important because it is thought that multiple variants in
susceptibility genes contribute to impairment of glucose
homeostasis in diabetes through the sum of multiple
negative variants (33).
Interestingly, insulin receptor
/ heterozygotes secrete
more insulin and have lower isolated islet insulin content.
This may reﬂect the higher levels of secretion as a result of
insulin resistance.
Sox proteins are dependent on other transcription fac-
tors as partner proteins for efﬁcient gene activation
(34,35). Speciﬁcity of Sox proteins are therefore reliant on
different binding partners, which may explain the diverse
roles in different tissues and developmental stages (36).
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FIG. 6. A and B: Quantitative PCR of corresponding RNAs from gene-speciﬁc knockdowns in Ins1 cells. A: Gck gene expression is markedly
reduced in cells transfected with Gck siRNA compared with nonsense (ns) or Sox4 siRNA–transfected cells. B: Sox4 gene expression is markedly
reduced in cells transfected with Sox4 siRNA compared with nonsense or Gck siRNA–transfected cells. Data represent the mean of three
experimental (i.e., biological) replicates with three technical replicates of each. C: Insulin secretion in response to glucose (0, 2, or 20 mmol/l)
or 200 mol/l tolbutamide (Tol) from INS1 cells transfected with Sox4 siRNA (black diagonal stripe bars, n  6; and black bars, n  6), Gck siRNA
(white bars, n  6), or nonsense siRNA (cross hatch bars, n  6). The data are the mean of three separate experiments each of six replicates of
1  10
5 cells. Statistical analysis by Student’s t test compared with nonsense siRNA control, where *P < 0.05 and **P < 0.01.
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2242 DIABETES, VOL. 57, AUGUST 2008Elucidation of the binding partner of Sox4 in adult islets
may lead to the identiﬁcation of the genes it regulates.
Sinner et al. (37) have recently reported that in colon
carcinoma cells, there is an interaction between Sox4 and
Sox17 with -catenin and TCF4. They propose a role for
these Sox genes in regulating Wnt signaling. Sox4 was
shown to interact with either -catenin or TCF4.I n
contrast, Sox17 bound cooperatively with both -catenin
and TCF4. It will be very interesting to determine whether
these interactions are found in the -cell, given the impli-
cation of TCF7L2 and Wnt signaling in insulin secretion
(rev. in 38).
Type 2 diabetes is a multifactorial disease resulting from
the interaction of genetic and environmental factors and
develops as a result of both insulin resistance and defects
in insulin secretion. We have clearly demonstrated a role
for Sox4 in glucose-stimulated insulin release in adult
pancreatic -cells and in causing mild but signiﬁcant
glucose intolerance. It will be important to assess whether
Sox4 has a role in contributing to type 2 diabetes in
humans or to monogenic MODY type diabetes. Further
characterization of the role of Sox4 in the adult -cell will
aid us in understanding the complex picture of transcrip-
tional regulation in this important cell.
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